VERTAP

RESPONSABLE DEL GRUP
MARCEVAP - Josep_Lluis_Ballve
José Luis Ballvé Moreno
ballvejl@gmail.com
avatar_grups_recerca.png

Publicacions

Efficacy of an electronic reminder for HIV screening in primary healthcare based on indicator conditions in Catalonia (Spain)

C. AGUSTI, O. CUNILLERA, J. ALMEDA, J. MASCORT, R. CARRILLO, C. OLMOS, A. MONTOLIU, M. ALBERNY, I. MOLINA, L. CAYUELAS and J. CASABONA
2022 Sep 1; . doi:10.1111/hiv.13270; PMID:35285143

  • Ans: 01/09/2022
  • FI: 3

Objective The aim of this study was to assess the efficacy of an electronic reminder in primary healthcare in patients diagnosed with an indicator condition (IC) to improve HIV screening. Methods We developed a prospective interventional study in 51 primary healthcare centres in Barcelona randomly assigned into one of two study groups: control and alert. Between June 2018 and May 2019, an electronic reminder appeared in the electronic medical record each time a diagnosis of an IC in patients aged 16-65 years was registered in the alert group. We assessed HIV testing rates within 4 months following the diagnosis of an IC. Results In all, 13 000 patients were diagnosed with at least one IC. HIV testing was more likely in the alert group than in the control group. The electronic reminder multiplied the odds of being tested in men by 1.26 [95% confidence interval (CI): 1.04-1.52, p = 0.019], by 1.77 (95% CI: 1.33-2.38, p < 0.001) among patients aged < 50 years , and by 1.51 (95% CI: 1.20-1.92, p < 0.001) in diagnoses of IC other than a sexually transmitted infection (STI) or an AIDS-defining illness. Five (0.08%) cases of HIV were detected in the control group and 10 (0.17%) in the alert group. Conclusions Implementing an electronic reminder had a positive impact on HIV screening rates in patients diagnosed with an IC. The alert was more effective among older patients, those living in less socioeconomically deprived neighbourhoods, and those with an IC other than an STI or an AIDS-defining illness.

Trends in glycemic control, cardiovascular risk factors and chronic complications of type 2 diabetes, 2012-2016, in a healthcare area of Barcelona

I. LOPEZ-COBO, L. RODRIGUEZ-LATRE, O. CUNILLERA, I. RUIZ, S. COPETTI, M. ALBAREDA and L. VILA
2022 Aug 1; . doi:10.1016/j.diabres.2022.110014; PMID:35870572

  • Ans: 01/08/2022
  • FI: 5.1

Aims: This study aimed to analyse the evolution of the metabolic control, cardiovascular risk factors and chronic complications in a Type 2 Diabetes (T2D) population in a healthcare area of Barcelona. Methods: We carried out a comparative study of T2D patients (20.457) between 2012 and 2016 (data recorded in the “Electronic Clinical-Station in Primary Care “) concerning: age, gender, body mass index (BMI), arterial blood pressure (BP), HbA1c, LDL-Cholesterol, smoking, heart failure (HF), micro and macrovascular complications.Results: Average HbA1c was 6.9 % in 2012 and 7 % in 2016 (Non significant differences)(NS). In 2012, 57.9 % of patients presented proper glycaemic control, 42.8 % LDL-Cholesterol < 100 mg/dL and 76.9 % BP < 140/90 while in 2016 it was 61.2 % (NS), 59.2 % (p = 0.001) and 82.9 % (p = 0.016) respectively. No changes were found in BMI or active smoking. Significant increases were found in the prevalence of microvascular compli-cations, HF and peripheral vasculopathy (PV). Patients with vascular diseases (PVD) and adequate metabolic control increased from 57.5 % to 62.7 % (p = 0.006). Albuminuria > 30 mg/g were more frequent among PVD. Conclusions: Between 2012 and 2016 it was observed that, amongst our study population, glycaemic control was steady and cholesterol and BP levels were improved, while there was a significant increase of diabetic compli-cations, HF and PV.

Effectiveness of a training intervention to improve the management of vertigo in primary care: a multicentre cluster-randomised trial, VERTAP

J. PATINO, J. MORENO, Y. MATOS, J. ORTEGA, O. PUERTOLAS, R. MUNOZ, I. BALBOA, X. COMPTA, O. AGUDELO, S. MUNOZ, V. RODRIGUEZ, A. CORTES and E. RODRIGUEZ
2022 Jul 29; . doi:10.1186/s13063-022-06548-7; PMID:35906606

  • Ans: 29/07/2022
  • FI: 2.5

Background: Benign paroxysmal positional vertigo (BPPV) is the most common type of vertigo. While BPPV is best treated with canalicular repositioning manoeuvres, they are not routinely performed in primary care (PC).
Methods: To evaluate the effectiveness of blended training (online and face-to-face) on the diagnosis and management of vertigo to improve adherence of family doctors to clinical practice guidelines, we designed a community multicentre cluster-randomised open-label trial with an intervention (IG) and a control (GC) group of 10 primary care teams (PCT) each. Outcome variables will be ICD-10 diagnostic codes (proportion of nonspecific diagnoses such as dizziness and vertigo versus specific diagnoses such as BPPV, vestibular neuritis, and Meniere’s disease); number of referrals to ENT or neurology specialists; prescription of antivertigo agents; and duration of sick leave due to vertigo. The baseline comparability of the two study groups will be analysed to ensure homogeneity. A description of all baseline variables will be performed. Student’s t-test will be used to evaluate the differences between the groups. Logistic regression multivariate analysis will be performed to study the relationship between baseline variables of professionals and centres with outcome variables.
Discussion: With the improvement of the diagnosis and management of vertigo by family doctors after this training, we expect an increase in the proportion of specific diagnoses, a decrease in the prescription of antivertigo agents, a decrease in referrals to ENT or neurology specialists and a reduction in the duration of sick leave due to temporary disability. The blended training will be easily expanded within primary care services, since it is mainly delivered online, with a single face-to-face session to ensure that the manoeuvres have been adequately learned.

Montelukast and COVID-19-related complications in people with SARS-CoV-2 infection: A population-based observational study

F. CORDERO, S. MONNE, J. ORTEGA, S. CONTRERAS-MARTOS, D. OUCHI, M. GINER-SORIANO, R. PEDROS and B. GONZALEZ
2022 May 1;

  • Ans: 01/05/2022
  • FI: 3.1
Double-blind placebo-controlled randomized clinical trial to assess the efficacy of montelukast in mild to moderate respiratory symptoms of patients with long COVID: E-speranza COVID-19 Project study protocol

S. MONNE, F. CORDERO, G. MUNOZ, J. ORTEGA, S. MARTOS, O. PUERTOLAS, A. SANGENIS, R. PEDROS, R. PEDROS and M. GONZALEZ
2022 May 1;

  • Ans: 01/05/2022
  • FI: 3.1

Patronat

Col·laboradors

Acreditacions